Psychedelic Medicine
November 2, 2026
John D. Gault, Erin Almklov, Shirley Tang et al.
Background: Evidence supporting psychedelic-assisted psychotherapy (PAP) for treating posttraumatic stress disorder, depression, and other historically difficult to treat mental health disorders is growing rapidly. Interest from the public and within the US government to provide access to these treatments has also grown. Considering the gap between discovery of effective treatments and...
Psychiatric Research and Clinical Practice
July 2, 2026
Kush V. Bhatt, Tara Austin, Danny Alam et al.
Objective This study evaluated whether intramuscular (IM) ketamine is non‐inferior to intranasal (IN) esketamine for treatment‐resistant depression (TRD) and assessed differences in safety and healthcare costs. Methods In a retrospective, observational sequential cohort at the VA San Diego, 179 Veterans with TRD received eight treatments of either IN esketamine ( n = 89) or IM ketamine ( n =...
Psychedelic Medicine
August 1, 2025
Kush V. Bhatt, Jason Compton, Em Ellerman et al.
1 citation
Mystical experiences are powerful experiences that may have therapeutic value. Ketamine, a dissociative anesthetic, has shown potential to induce mystical experiences. However, little research has explored this phenomenon, particularly in treatment-resistant depression. We analyzed clinical data from 60 veterans with treatment-resistant depression receiving a total of 189 ketamine treatments....
Psychological Trauma: Theory, Research, Practice and Policy
October 31, 2024
Caitlin L Mclean, Ashley Faytol, Gage Chu et al.
1 citation
While mobile delivery can help increase access to evidence-based treatment for veterans with posttraumatic stress disorder (PTSD), feasibility and acceptability are of concern with the potential for high attrition rates and limited participation. The Mantram Repetition Program (MRP), a meditation-focused approach with documented efficacy for reducing symptoms of PTSD and insomnia, was adapted...